After completing $121 million in Series C financing last year, Sema4 pondered how much more capital it would need—and the best way to raise it—in order to offer more of the holistic precision medicine solutions on which it had begun to gain traction from health systems. Sema4 harnesses 21st century…

Oxford Nanopore, the pioneer developer of DNA/RNA nanopore sensing tools that include its pocket-sized MinION DNA/RNA sequencer, has disclosed plans for an initial public offering that could value the company at a reported £4 billion ($5.5 billion). Oxford Nanopore seeks to trade its shares on the London Stock Exchange. “Ever…

REGISTER NOW Broadcast Date: February 9, 2021Time: 8:00 am PT, 11:00 am ET, 17:00 CET The number of targeted therapies and the complexity of biomarker detection linked to these therapies has grown over the last decade. To accommodate it, the drug development process must also evolve. In this Clinical OMICs…

Thermo Fisher Scientific announced on Tuesday that it will expand the scope of it work with pharma Daiichi Sankyo via a new co-development agreement for a companion diagnostic (CDx) designed to identify non-small cell lung cancer (NSCLC) patients with human epidermal growth factor receptor 2 (HER2) mutations who may be…

Royal Philips and the Texas MD Anderson Cancer Center announced yesterday a collaboration that will provide oncologists world-wide with evidence-based cancer therapy recommendations and clinical trials information based on a patient’s genomic profile via Philips’ oncology informatics platform tied into the Precision Oncology Decision Support (PODS) system at MD Anderson.…

The first cell atlas of the human thymus gland has been mapped using scRNA-seq and it could lead to new immune therapies to treat cancer and autoimmune disease. The thymus makes T cells, and these are currently being used to treat B-cell lymphoma and leukemia. CAR-T—chimeric antigen receptor T-cell—therapy is…

Researchers at the Karolinska Institutet in Sweden say they have developed a new cheap method that can identify highly heterogeneous tumors that tend to be aggressive, and therefore need to be treated more aggressively. The technique is presented in an article (“CUTseq is a versatile method for preparing multiplexed DNA…

REGISTER NOW Broadcast Date: October 1, 2019Time: 8:00 am PT, 11:00 am ET, 17:00 CET Accurate monitoring of cell signaling pathway proteins, particularly tyrosine phosphorylation (pTyr) on these proteins, has proven challenging due to the low cellular abundance of these targets and lack of standardized targeted proteomic methodologies and reagents.…

New research out of the Scripps Research Institute is showing early promise in being able to address treatment for a form of cancer which, to date, has no targeted therapies—HER2-negative breast cancer. The study, published in the Journal of the American Chemical Society, from the research lab of Matthew D.…

Mission Bio said today it has completed a $30 million Series B financing, with plans to expand and further develop its single-cell DNA genomics platform for oncology; broaden the scope of its activity into CRISPR and other gene editing applications; and expand overseas. Charlie Silver, Mission Bio co-founder and CEO,…

Guardant Health, the developer of genomic liquid biopsy tests focused on detecting cancer, will seek to raise up to $100 million in gross proceeds through an initial public offering (IPO), according to an S-1 registration statement filed yesterday with the U.S. Securities and Exchange Commission. Guardant didn’t spell out how…

Personal Genome Diagnostics (PGDx) announced it will collaborate with Five Prime Therapeutics to develop a plasma-based companion diagnostic assay for use with Five Prime's first-in-class investigational drug candidate, bemarituzumab. The diagnostic assay will be used in Five Prime's global registrational study of bemarituzumab in combination with 5-fluorouracil (5-FU), leucovorin, and…